We are live on ! Find out more
OWP

Old Well Partners Portfolio holdings

AUM $4.55M
1-Year Est. Return 27.75%
This Fund
S&P 500
This Quarter Est. Return
+18.13%
1 Year Est. Return
+27.75%
3 Year Est. Return
+97.85%
5 Year Est. Return
+345.65%
10 Year Est. Return
AUM
$203M
AUM Growth
+$8.61M
Cap. Flow
-$4.86M
Cap. Flow %
-2.4%
Top 10 Hldgs %
65.71%
Holding
57
New
15
Increased
13
Reduced
11
Closed
12

Top Buys

Rank Stock Value
1
JOYY
JOYY Inc
JOYY
+$8.76M
2
XP icon
XP
XP
+$7.25M
3
GDS icon
GDS Holdings
GDS
+$4.82M
4
AMZN icon
Amazon
AMZN
+$3.01M
5
JD icon
JD.com
JD
+$2.76M

Top Sells

Rank Stock Value
1
FUTU icon
Futu Holdings
FUTU
+$14.9M
2
BILI icon
Bilibili
BILI
+$8.86M
3
PDD icon
Pinduoduo
PDD
+$4.92M
4
ONC
BeOne Medicines Ltd
ONC
+$4.4M
5
ZG icon
Zillow
ZG
+$1.94M

Sector Composition

Rank Sector Weight
1 Consumer Discretionary 39.61%
2 Technology 19.1%
3 Financials 14.33%
4 Communication Services 9.66%
5 Healthcare 7.48%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
KOD icon
26
Kodiak Sciences
KOD
$2.47B
$289K 0.14%
2,545
ALDX icon
27
Aldeyra Therapeutics
ALDX
$95.3M
$279K 0.14%
+23,487
New +$270K
DMTK
28
DELISTED
DermTech, Inc. Common Stock
DMTK
$266K 0.13%
5,246
-7,166
-58% -$375K
ANAB icon
29
AnaptysBio
ANAB
$1.58B
$260K 0.13%
+12,052
New +$304K
PRTA icon
30
Prothena Corp
PRTA
$443M
$256K 0.13%
+10,191
New +$192K
ISEE
31
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$251K 0.12%
+40,547
New +$246K
FATE icon
32
Fate Therapeutics
FATE
$267M
$244K 0.12%
2,960
DGNS
33
DELISTED
Dragoneer Growth Opportunities Corp. II Class A Ordinary Shares
DGNS
$242K 0.12%
+23,560
New +$279K
MRUS
34
DELISTED
Merus
MRUS
$224K 0.11%
+10,722
New +$247K
MRTX
35
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$211K 0.1%
+1,229
New +$243K
BLFS icon
36
BioLife Solutions
BLFS
$1.58B
$204K 0.1%
5,668
VOR icon
37
Vor Biopharma
VOR
$1.09B
$202K 0.1%
+234
New +$198K
IGMS
38
DELISTED
IGM Biosciences
IGMS
$201K 0.1%
2,619
AGCB
39
DELISTED
Altimeter Growth Corp 2
AGCB
$190K 0.09%
+18,258
New +$218K
SLDB icon
40
Solid Biosciences
SLDB
$781M
$188K 0.09%
+2,261
New +$250K
ADVM
41
DELISTED
Adverum Biotechnologies
ADVM
$182K 0.09%
+1,844
New +$221K
LABP
42
DELISTED
Landos Biopharma, Inc. Common Stock
LABP
$176K 0.09%
+1,832
New +$239K
BCEL
43
DELISTED
Atreca, Inc. Class A Common Stock
BCEL
$154K 0.08%
10,023
ARYD
44
DELISTED
ARYA Sciences Acquisition Corp IV Class A Odinary Shares
ARYD
$149K 0.07%
+14,269
New +$154K
AGCUU
45
DELISTED
Altimeter Growth Corp Unit
AGCUU
$133K 0.07%
10,910
-1,300
-11% -$18.5K
LONA
46
LeonaBio Inc
LONA
$66.5M
-770
Closed -$264K
JYNT icon
47
The Joint Corp
JYNT
$123M
-57,056
Closed -$1.5M
NAUT icon
48
Nautilus Biotechnolgy
NAUT
$152M
-12,954
Closed -$141K
NKTX icon
49
Nkarta
NKTX
$161M
-4,532
Closed -$279K
OBIO icon
50
Orchestra BioMed
OBIO
$231M
-14,300
Closed -$183K

Similar funds

Old Well Partners's Q1 2021 Portfolio in Review

As of Q1 2021, Old Well Partners held 57 positions worth $203M, up 4.4% from $194M the previous quarter. Its ten largest holdings account for 66% of the portfolio.

Old Well Partners's Q1 2021 filing shows 15 new, 13 increased, 11 reduced and 12 closed positions. Its largest new stake was JOYY Inc: 81,100 shares worth $7.6M. The largest sale was Futu Holdings, an estimated $14.9M.

By sector, the portfolio is most concentrated in Consumer Discretionary at 40% of assets, down from 44% a quarter earlier, followed by Technology and Financials.

  • Old Well Partners's largest Q1 2021 buy was JOYY Inc: 81,100 shares worth $7.6M.
  • Old Well Partners added most to GDS Holdings in Q1 2021, an estimated $4.82M increase.
  • Old Well Partners's biggest Q1 2021 reduction was Futu Holdings, cutting an estimated $14.9M.
  • Old Well Partners fully exited Zillow in Q1 2021, selling an estimated $1.94M.
  • Old Well Partners's ten largest holdings make up 66% of its $203M portfolio in Q1 2021.
  • Old Well Partners opened 15 new positions and closed 12 in Q1 2021.
  • Old Well Partners's portfolio value rose 4.4% quarter-over-quarter to $203M.

Based on Old Well Partners's 13F filing for Q1 2021, filed 17 May 2021.